SLC5A2 and anemia (phenotype): Although increased iron uptake and utilization in metabolizing tissues after treatment with an SGLT2 inhibitor requires further confirmation, available evidence suggests a potential synergy with therapeutic iron supplementation to replenish deficient iron stores, to further enhance myocardial energetics and to ameliorate anemia.